or Try an Advanced Search...

    Immune Diseases Stocks List

    Symbol Grade Name % Change
    TRML B Tourmaline Bio, Inc. 3.06
    TLSA C Tiziana Life Sciences plc -3.87
    REGN F Regeneron Pharmaceuticals, Inc. 0.64
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biotechnology Immunology Angiogenesis Antibodies Asthma Atherosclerosis Atopic Dermatitis Biopharmaceutical Bone Breakthrough Therapy Cancer Cardiovascular Disease Cartilage Cholesterol Clinical Development Clinical Research Colorectal Cancer Dermatitis Disorders Human Diseases

    Related ETFs - A few ETFs which own one or more of the above listed Immune Diseases stocks.

    Symbol Grade Name Weight
    BBH D Market Vectors Biotech ETF 8.14
    IBB C iShares Nasdaq Biotechnology Index Fund 7.21
    IBBQ D Invesco Nasdaq Biotechnology ETF 6.52
    FPX B First Trust IPOX-100 Index Fund 5.71
    CANC C Tema Oncology ETF 5.42
    View all Immune Diseases ETFs...
    Compare ETFs
    Compare BBH to FPX Compare FPX to CANC Compare IBBQ to CANC

        Immune Diseases Stocks Recent News

        Date Stock Title
        Nov 1 TLSA Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
        Nov 1 REGN What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity?
        Nov 1 REGN Regeneron Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
        Nov 1 REGN Regeneron: Investors In Panic Mode On Increased Eylea Fears
        Nov 1 REGN Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
        Nov 1 REGN Regeneron Pharmaceuticals Inc (REGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth ...
        Nov 1 REGN Q3 2024 Regeneron Pharmaceuticals Inc Earnings Call
        Oct 31 REGN Regeneron Pharmaceuticals files automatic mixed securities shelf
        Oct 31 REGN Eylea headwinds said to be behind Regeneron’s post-Q3 plunge
        Oct 31 REGN Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
        Oct 31 REGN Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Transcript
        Oct 31 REGN Regeneron down 10% despite top and bottom line beats
        Oct 31 REGN Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom
        Oct 31 REGN Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
        Oct 31 REGN REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
        Oct 31 REGN Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
        Oct 31 REGN Regeneron beats results estimates on demand for eczema treatment, eye drug
        Oct 31 REGN Regeneron: Q3 Earnings Snapshot
        Oct 31 REGN Regeneron Pharmaceuticals Non-GAAP EPS of $12.46 beats by $0.75, revenue of $3.72B beats by $50M
        Oct 31 REGN Regeneron Reports Third Quarter 2024 Financial and Operating Results
        Related Industries: Biotechnology
        Related Stock Lists: Biotechnology Immunology Angiogenesis Antibodies Asthma Atherosclerosis Atopic Dermatitis Biopharmaceutical Bone Breakthrough Therapy Cancer Cardiovascular Disease Cartilage Cholesterol Clinical Development Clinical Research Colorectal Cancer Dermatitis Disorders Human Diseases
        Immune Diseases

        Immune diseases are conditions that occur when the body's immune system malfunctions and attacks healthy cells, tissues, and organs. Examples of immune diseases include autoimmune disorders such as lupus, rheumatoid arthritis, type 1 diabetes, and multiple sclerosis.

        Browse All Tags